Industry

– LINZESS (Iinaclotide) EUTRx prescription demand growth in Q2 2022 increased 9% year-over-year – – GAAP net income of $37 million and adjusted EBITDA of $56 million; ended Q2 2022 with $504 million in cash and cash equivalents – – Completes Board of Directors authorized share repurchase program; repays remaining principal amount of the 2022 … [Read more…]

CTP-543 Positive Topline Results Reported in THRIVE-AA1 and THRIVE-AA2 Phase 3 Studies in Alopecia Areata CTP-543 Has the Potential to Address an Important Unmet Need for a Large, Underserved Patient Population Conference Call Scheduled Today at 8:30 a.m. ET; Online Registration Required to Access Dial in and PIN for Live Call to Ask Questions LEXINGTON, … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a discussion at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10 at 12:30 p.m. ET. An audio webcast of the presentation will be available under the “Investors … [Read more…]

Second quarter 2022 core Lung Diagnostic revenue of $7.3 million increased 52% over the comparable period in 2021; Received Medicare coverage for the Nodify CDT® Lung Nodule Test; Announced strategic arrangements during the quarter (Royal Philips, Memorial Sloan Kettering Cancer Center and Bio-Rad); Reaffirm 2022 revenue outlook of between $37.5 million and $39.5 million; Conference … [Read more…]

SEATTLE–(BUSINESS WIRE)–#earnings–NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast presentations from two upcoming healthcare conferences. 42nd Annual Canaccord Global Growth Conference Wednesday, August 10th Brad Gray, NanoString’s chief executive officer, will participate in a spatial biology panel titled, … [Read more…]

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–$MD–Pediatrix Medical Group, Inc. (NYSE: MD), the nation’s leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.36 per share for the three months ended June 30, 2022. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.47. For … [Read more…]

Net revenue increased to $28.2 million for Q2 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS® (voclosporin) for 2022 Continued increases in LUPKYNIS Patients on Treatment; Steady Conversion Rates and Payor Coverage EMA review of LUPKYNIS remains on track with decision expected by the end of Q3 2022 $391.7 million … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “North America Idiopathic Pulmonary Fibrosis Market Size, Share & Industry Trends Analysis Report By Drug Type, By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Providers, By Country and Growth Forecast, 2021-2027” report has been added to ResearchAndMarkets.com’s offering. The North America Idiopathic Pulmonary Fibrosis Market is expected to witness market growth of … [Read more…]

LONDON–(BUSINESS WIRE)–AIBODY, the world’s first Physiology-as-a-Service platform, announced today that it has signed a collaboration agreement with the German Heart Centre Berlin (DHZB), a leading medical research institute specializing in cardiovascular disease. This agreement focuses on the development of a suite of innovative solutions that will facilitate the diagnosis and treatment of congenital heart disease. … [Read more…]

Approval marks the first all-oral, once-daily, fixed-duration Bruton’s tyrosine kinase (BTK) inhibitor-based regimen for first-line treatment of CLL BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission granted marketing authorisation for the expanded use of IMBRUVICA® (ibrutinib) in an all-oral, fixed-duration (FD) treatment combination with venetoclax (I+V) for … [Read more…]